Furthermore, studies indicate that diabetics treated with glucagon‐like peptide‐1 (GLP‐1) receptor agonists have a reduced risk of PD compared to those on other anti-diabetic medications, suggesting possible neuroprotective effects [9, 10]. Here, GLP1R is linked to Parkinson disease.